Whitnell & Co. Has $1.67 Million Position in Merck & Co., Inc. (NYSE:MRK)

Share on StockTwits

Whitnell & Co. raised its stake in Merck & Co., Inc. (NYSE:MRK) by 33.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 19,865 shares of the company’s stock after purchasing an additional 5,000 shares during the period. Whitnell & Co.’s holdings in Merck & Co., Inc. were worth $1,672,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Titan Capital Management LLC CA acquired a new position in shares of Merck & Co., Inc. in the second quarter valued at about $25,000. LFA Lugano Financial Advisors SA grew its stake in shares of Merck & Co., Inc. by 250.0% in the second quarter. LFA Lugano Financial Advisors SA now owns 315 shares of the company’s stock valued at $26,000 after acquiring an additional 225 shares in the last quarter. JJJ Advisors Inc. acquired a new position in shares of Merck & Co., Inc. in the second quarter valued at about $27,000. Cumberland Partners Ltd acquired a new position in shares of Merck & Co., Inc. in the second quarter valued at about $40,000. Finally, Fusion Family Wealth LLC grew its stake in shares of Merck & Co., Inc. by 268.2% in the second quarter. Fusion Family Wealth LLC now owns 486 shares of the company’s stock valued at $41,000 after acquiring an additional 354 shares in the last quarter. Hedge funds and other institutional investors own 74.95% of the company’s stock.

Several research firms recently commented on MRK. Argus upped their price target on shares of Merck & Co., Inc. to $105.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Bank of America assumed coverage on shares of Merck & Co., Inc. in a research report on Wednesday, October 16th. They set a “neutral” rating and a $90.00 price objective for the company. Societe Generale set a $105.00 price objective on shares of Merck & Co., Inc. and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Mizuho upped their price objective on shares of Merck & Co., Inc. from $97.00 to $100.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Finally, Credit Suisse Group reaffirmed a “buy” rating and set a $95.00 price objective on shares of Merck & Co., Inc. in a research report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have given a buy rating to the company. Merck & Co., Inc. currently has a consensus rating of “Buy” and an average price target of $95.13.

Shares of MRK stock traded up $0.71 on Friday, reaching $83.59. The company had a trading volume of 6,053,527 shares, compared to its average volume of 10,105,755. The stock has a market capitalization of $212.31 billion, a PE ratio of 19.26, a price-to-earnings-growth ratio of 1.80 and a beta of 0.54. The company has a quick ratio of 0.92, a current ratio of 1.21 and a debt-to-equity ratio of 0.82. Merck & Co., Inc. has a one year low of $70.89 and a one year high of $87.35. The business’s 50-day moving average is $84.01 and its 200 day moving average is $82.77.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, October 29th. The company reported $1.51 EPS for the quarter, topping analysts’ consensus estimates of $1.24 by $0.27. The firm had revenue of $12.40 billion during the quarter, compared to analysts’ expectations of $11.59 billion. Merck & Co., Inc. had a net margin of 20.26% and a return on equity of 47.94%. The business’s revenue for the quarter was up 14.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.19 earnings per share. On average, sell-side analysts forecast that Merck & Co., Inc. will post 5.16 earnings per share for the current fiscal year.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Featured Article: If I purchase shares through a brokerage account, am I the holder of record?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.